NAVIPPRO™ and one of its components, ASI-MV® Connect are products that are wholly owned by Inflexxion, Inc. Authors Butler, Budman, and Katz are shareholders in Inflexxion, Inc. Authors Licari, Cassidy, Lioy, and Dickinson are employees of Inflexxion. Authors Brownstein, Benneyan, and Green are consultants to Inflexxion. Products of the industry sponsors are monitored by the NAVIPPRO™ system. No authors are employees of the industry sponsors. .
National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse†
Article first published online: 17 OCT 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 17, Issue 12, pages 1142–1154, December 2008
How to Cite
Butler, S. F., Budman, S. H., Licari, A., Cassidy, T. A., Lioy, K., Dickinson, J., Brownstein, J. S., Benneyan, J. C., Green, T. C. and Katz, N. (2008), National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidem. Drug Safe., 17: 1142–1154. doi: 10.1002/pds.1659
- Issue published online: 25 NOV 2008
- Article first published online: 17 OCT 2008
- Manuscript Accepted: 14 AUG 2008
- Manuscript Revised: 11 AUG 2008
- Manuscript Received: 24 SEP 2007
- post-marketing surveillance;
- pharmaceutical surveillance;
- drug surveillance;
- substance abuse treatment
The National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™) is a scientific, comprehensive risk management program for scheduled therapeutics. NAVIPPRO™ provides post-marketing surveillance, signal detection, signal verification and prevention and intervention programs. Here we focus on one component of NAVIPPRO™ surveillance, the Addiction Severity Index-Multimedia Version® (ASI-MV®) Connect, a continuous, real-time, national data stream that assesses pharmaceutical abuse by patients entering substance abuse treatment by collecting product-specific, geographically-detailed information.
We evaluate population characteristics for data collected through the ASI-MV® Connect in 2007 and 2008 and assess the representativeness, geographic coverage, and timeliness of report of the data. Analyses based on 41 923 admissions to 265 treatment centers in 29 states were conducted on product-specific opioid abuse rates, source of drug, and route of administration.
ASI-MV® Connect data revealed that 11.5% of patients reported abuse of at least one opioid analgesic product in the 30 days prior to entering substance abuse treatment; differences were observed among sub-populations of prescription opioid abusers, among products, and also within various geographic locations.
The ASI-MV® Connect component of NAVIPPRO™ represents a potentially valuable data stream for post-marketing surveillance of prescription drugs. Analyses conducted with data obtained from the ASI-MV® Connect allow for the characterization of product-specific and geospatial differences for drug abuse and can serve as a tool to monitor responses of the abuse population to newly developed “abuse deterrent” drug formulations. Additional data, evaluation, and comparison to other systems are important next steps in establishing NAVIPPRO™ as a comprehensive, post-marketing surveillance system for prescription drugs. Copyright © 2008 John Wiley & Sons, Ltd.